PURAPHARM (01498)
| Auditor | From | To | Release Date / Document Links | Reason for Change |
|---|---|---|---|---|
| BDO | 28-Nov-24 | |||
| Ernst & Young | 25-Jun-15 | 28-Nov-24 | Could not reach a consensus on the audit fee. EY further confirmed that, other than the emphasis of the material uncertainty related to the going concern of the Group which existed at 31 December 2023 as set out in the respective audit report dated 28 March 2024, EY does not have any other matters that would like to bring to the attention to the shareholders or creditors of the Company. |